PAVM PAVM
Company Profile ↓Company Overview
PAVM (PAVM) is a publicly traded company listed on with a market capitalization of $4.68M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 2.7.
Carries low leverage with a debt-to-equity ratio of 0.39.
Recent Developments
- Dec 2025 Revenue of $71.00K (-97.6% YoY); net profit $401.00K.
- Trailing 12 Months Year-on-year growth — revenue -97.6%, earnings -99.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -42.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -42.68% |
| 1 Year: | -97.63% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -98.99% |
Stock Price Performance
| 1 Year: | -68.06% |
| 6 Months: | -47.34% |
| 3 Months: | -37.39% |
| 1 Month: | -4.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.82 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -42.7% CAGR over 5 years.
- Trading 69.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 200.00K | 189.00K | - | 76.00K | 446.00K | 166.00K | 791.00K | 1.01M | 979.00K | 996.00K | - | 8.00K | 6.00K | 5.00K | 52.00K | 22.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 36.00K | 41.00K | 55.00K | 85.00K | 97.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.00K | -180.00K | - | - | - | - | - | - | - | - | - | -28.00K | -35.00K | -50.00K | -33.00K | -75.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.40M | 4.60M | 4.63M | 6.62M | 7.79M |
| Operating Income | - | - | - | - | -696.88K | -1.31M | -1.93M | - | -2.16M | -2.02M | -1.97M | -1.94M | -2.74M | -2.57M | -3.14M | -3.32M | -3.24M | -5.25M | -5.01M | -5.53M | -8.08M | -12.97M | -13.67M | -19.64M | -23.48M | -23.37M | -20.40M | -16.48M | -15.53M | -14.04M | -13.68M | -11.58M | - | -5.43M | -4.63M | -4.68M | -6.65M | -7.87M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.67M | -12.30M | -5.98M | -2.73M | -1.04M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00K | 4.00K | 8.00K | 5.00K | 3.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.62M | -12.32M | -6.01M | -2.76M | -1.06M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -146.34K | -360.61K | -538.90K | -730.75K | -696.88K | -1.31M | -1.93M | -1.71M | -4.27M | -989.71K | -5.13M | -2.83M | -5.07M | -3.25M | -3.54M | -3.59M | -3.08M | -14.47M | -5.58M | -5.48M | -9.43M | -11.47M | -12.23M | -16.87M | -25.52M | -26.13M | -17.93M | -14.54M | -17.67M | -15.21M | -10.83M | 64.40M | - | 18.97M | -11.92M | -5.38M | -1.26M | -60.00K |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.29 | -0.29 | -2.78 | -2.10 | -2.38 | -2.62 | -1.19 | 1.44 | - | 10.10 | -22.20 | -8.70 | -61.50 | -4.42 |
| R&D Expense | 16.00K | 67.45K | 264.53K | 141.34K | 179.14K | 355.00K | 578.47K | 606.97K | 656.71K | 701.74K | 704.87K | 563.22K | 1.15M | 1.17M | 1.45M | 1.41M | 1.52M | 2.63M | 2.13M | 2.62M | 3.31M | 4.26M | 5.30M | 5.93M | 6.74M | 6.20M | 4.05M | 3.47M | 3.16M | 1.94M | 1.64M | 1.54M | - | 787.00K | 790.00K | 1.09M | - | 1.39M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 377.00K | 2.45M | 3.00M | 71.00K |
| Cost of Revenue | - | - | - | - | - | - | - | 3.61M | 6.42M | 4.84M | 218.00K |
| Gross Profit | - | - | - | - | - | - | - | -3.24M | -3.97M | -1.84M | -147.00K |
| Operating Expenses | - | - | - | - | - | - | - | 87.85M | 64.83M | 42.53M | 21.24M |
| Operating Income | - | -5.65M | -8.03M | -10.56M | -14.29M | -23.35M | - | -91.09M | -68.80M | -44.38M | -21.39M |
| EBITDA | - | - | - | - | - | - | - | -99.50M | -75.74M | 29.67M | -2.34M |
| Interest Expense | - | - | - | - | - | - | - | 1.28M | 589.00K | 45.00K | 21.00K |
| Pretax Income | - | - | - | - | - | - | - | -103.24M | -79.26M | 28.43M | -2.47M |
| Tax Provision | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Net Income | -1.78M | -5.65M | -9.52M | -17.97M | -16.46M | -34.28M | - | -88.98M | -64.17M | 39.79M | 401.00K |
| Diluted EPS | - | - | - | - | - | - | - | -450.90 | -274.80 | 15.00 | 1.84 |
| R&D Expense | 489.33K | 1.72M | 2.62M | 4.25M | 6.63M | 10.96M | 19.85M | 25.34M | 14.28M | 5.93M | 4.49M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.21M | 870.42K | 1.64M | 8.50M | 7.24M | 19.78M | - | 53.98M | 33.12M | 30.66M | 38.81M |
| Current Assets | - | - | - | - | - | - | - | - | 43.93M | 24.50M | 2.16M | 2.56M |
| Cash & Equivalents | 839.08K | 767.27K | 585.68K | 1.54M | 8.22M | 6.22M | 17.26M | - | 39.74M | 19.64M | 1.19M | 1.54M |
| Inventory | - | - | - | - | - | - | - | - | 261.00K | 539.00K | 266.00K | 239.00K |
| Receivables | - | - | - | - | - | - | - | - | 17.00K | 61.00K | 18.00K | 15.00K |
| Total Liabilities | - | - | 1.19M | 4.49M | 10.97M | 11.88M | 20.25M | - | 43.05M | 57.14M | 37.69M | 16.51M |
| Current Liabilities | - | 580.17K | 1.19M | 2.54M | 10.97M | 11.88M | - | - | 41.20M | 54.18M | 35.45M | 14.84M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | 36.64M | 48.73M | 31.86M | 13.35M |
| Total Equity | 794.83K | 633.92K | -319.07K | -2.85M | -2.31M | -3.82M | 1.90M | - | -9.68M | -53.83M | -2.50M | 33.97M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 210.02K | 285.95K | 373.30K | 927.93K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -6.61M | -8.79M | -13.36M | -21.91M | - | -70.98M | -52.04M | -33.55M | -5.21M |
| Investing Cash Flow | - | -5.30K | -26.61K | -27.00K | -55.00K | - | -4.74M | 758.00K | -16.18M | -31.00K |
| Financing Cash Flow | - | 7.56M | 15.50M | 11.38M | 33.01M | - | 38.21M | 31.17M | 31.28M | 5.59M |
| Capital Expenditure | -21.79K | -5.30K | -26.61K | -27.00K | -55.00K | - | -1.54M | -242.00K | -55.00K | -31.00K |
| Free Cash Flow | - | -6.61M | -8.81M | -13.38M | -21.97M | - | -72.53M | -52.28M | -33.61M | -5.24M |
| Net Change in Cash | - | - | - | - | - | - | -37.51M | -20.11M | -18.45M | 353.00K |
| Share Buybacks | - | - | - | 101.10K | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | -858.6% | -161.8% | -61.6% | -207.0% |
| Operating Margin % | - | - | - | - | - | - | - | -24,161.0% | -2,805.7% | -1,481.7% | -30,126.8% |
| Net Margin % | - | - | - | - | - | - | - | -23,602.9% | -2,617.3% | 1,328.6% | 564.8% |
| ROE % | -280.3% | 1,771.1% | 334.2% | 776.3% | 430.4% | -1,807.8% | - | 919.2% | 119.2% | -1,594.8% | 1.2% |
| ROCE % | - | 1,771.1% | 888.6% | 426.6% | 308.2% | - | - | -712.7% | 326.7% | 927.2% | -89.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PAVM
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Concert, a healthcare technology company …
Lucid Diagnostics to Participate in Upcoming Investor Conferences
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the follo…
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update…
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference…
How The PAVmed (PAVM) Narrative Is Shifting With Reworked Assumptions And A Lower Price Target
PAVmed’s latest analyst update keeps fair value unchanged at US$40.50 but comes alongside a US$44 cut to the price target that has drawn fresh attention. Analysts frame this move as a recalibration tied to updated assumptions rather than a …
PAVmed Inc. Q1 2026 Earnings Call Summary
Moby summary of PAVmed Inc.'s Q1 2026 earnings call
PAVM — Frequently Asked Questions
What is the current share price of PAVM?
As of 2026-08-05 17:25 PDT, PAVM trades at $5.04 on NASDAQ/NYSE. Its 52-week range is $4.35 to $16.65.
What is the market capitalisation of PAVM?
PAVM has a market capitalisation of $4.68M on NASDAQ/NYSE.
What is the P/E ratio of PAVM?
PAVM trades at a trailing price-to-earnings (P/E) ratio of 2.74. Its price-to-book (P/B) ratio is 0.14.
What is the return on equity (ROE) of PAVM?
PAVM has a return on equity (ROE) of 1.18%. Its return on capital employed (ROCE) is -89.22%.
Is PAVM a good stock to buy?
This page provides a data-driven analysis of PAVM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.